Clene Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Clene han disminuido a una tasa media anual de -15.3%, mientras que en la industria Biotechs los beneficios crecieron en un 12.7% anualmente. Los ingresos han ido creciendo a una tasa media de 39.7% al año.

Información clave

-15.3%

Tasa de crecimiento de los beneficios

11.1%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	39.7%
Rentabilidad financiera	-369.7%
Margen neto	-7,569.4%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Clene. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqCM:CLNN Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	1	-50	14	27
30 Sep 23	1	-40	15	28
30 Jun 23	1	-49	15	28
31 Mar 23	1	-28	16	31
31 Dec 22	0	-30	17	32
30 Sep 22	0	-24	18	34
30 Jun 22	0	15	19	33
31 Mar 22	1	17	21	31
31 Dec 21	1	-10	22	28
30 Sep 21	1	-13	18	23
30 Jun 21	1	-53	16	21
31 Mar 21	0	-55	10	18
31 Dec 20	0	-19	5	15
30 Sep 20	0	-24	5	14
30 Jun 20	0	-19	6	12
31 Mar 20	0	-16	6	11
31 Dec 19	0	-16	7	10

Ingresos de calidad: CLNN actualmente no es rentable.

Margen de beneficios creciente: CLNN actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: CLNN no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 15.3% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de CLNN en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: CLNN no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-8.9%).

Rentabilidad financiera

Alta ROE: CLNN tiene una rentabilidad financiera negativa (-369.71%), ya que actualmente no es rentable.

Clene Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Recent updates

Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension (LTE) Study Results at the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver

Clene Inc., Annual General Meeting, May 29, 2024

Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Clene Reports Significant Survival Benefit with Cnm-Au8® Treatment in Als Eap Compassionate Use Programs

Clene Receives Notice from Nasdaq the Company Has Not Regained Compliance with the Minimum Bid Price Requirement

Clene Inc. Reports Significant Improvement in Vision and Cognition with Cnm-Au8®? Treatment in Vision-MS Trial

Price target decreased by 11% to US$5.00

Clene Inc. and Clene Nanomedicine Inc. Announce Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement in Neurodegenerative Diseases

Independent Chairman of the Board recently bought US$103k worth of stock

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Clene Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

New major risk - Revenue and earnings growth

High number of new directors

Clene Inc. Announces Executive Changes

Consensus revenue estimates increase by 53%, EPS downgraded

Price target decreased by 13% to US$5.83

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Clene Receives Written Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with the Minimum Bid Price Requirement

New minor risk - Market cap size

New minor risk - Share price stability

Independent Director recently bought US$253k worth of stock

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine

Price target decreased by 20% to US$6.71

Consensus revenue estimates increase by 21%

New major risk - Shareholder dilution

Clene’S Cnm-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (Nfl) Levels in the Healey Als Platform Trial

Clene Inc. has completed a Follow-on Equity Offering.

Clene Receives Non-Compliance Notice From Nasdaq

Consensus revenue estimates increase by 27%

Consensus revenue estimates decrease by 53%, EPS upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 10% to US$8.57

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased by 10% to US$9.57

Clene Inc. Announces Resignation of Chidozie Ugwumba from the Board and All Committees

Clene Inc. Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8(R) Treatment Improved Brain Neuronal Structural Integrity

Clene Inc. Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg

Clene Inc. and Clene Nanomedicine Inc, Announce the Visionary-MS Trial Results Were Featured as A Platform Presentation by Professor Michael Barnett At the 14th Annual Singapore Pan-Asian Committee on Treatment and Research in Multiple Sclerosis Congress

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Independent Chairman of the Board recently bought US$2.9m worth of stock

High number of new directors

Investor sentiment deteriorated over the past week

Price target decreased to US$10.57

Clene Inc. and Clene Nanomedicine Inc. Reports Topline Results Demonstrating Survival Signal for Cnm-Au8 in Healey Als Platform Trial

Investor sentiment deteriorated over the past week

Clene slips 13% as lead asset fails in ALS study

Clene Inc. and its Wholly Owned Subsidiary Clene Nanomedicine Inc. Present Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference

Consensus estimates of losses per share improve by 12%

Independent Director recently bought US$183k worth of stock

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis

Investor sentiment deteriorated over the past week

Consensus forecasts updated

CEO, President & Director notifies of intention to sell stock

Clene ALS therapy gets EMA panel backing for orphan drug status

Clene Inc Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial

Investor sentiment improved over the past week

Clene Inc.(NasdaqCM:CLNN) dropped from Russell 2500 Value Index

Investor sentiment improved over the past week

Co-Founder & Chief Science Officer notifies of intention to sell stock

Independent Chairman of the Board recently bought US$155k worth of stock

Investor sentiment improved over the past week

Clene Inc. Announces the Presentation of New Data from the its Phase 2 RESCUE-ALS Study at the European Network to Cure ALS (ENCALS) Meeting 2022

Independent Chairman of the Board recently bought US$79k worth of stock

Investor sentiment improved over the past week

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

Desglose de ingresos y gastos
Beta